Peter Clark to Adenocarcinoma
This is a "connection" page, showing publications Peter Clark has written about Adenocarcinoma.
Connection Strength
0.694
-
Clark PE, Hall MC, Borden LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Lovato J, Harmon M, Torti FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006 Jun; 67(6):1257-61.
Score: 0.222
-
David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA. MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. Prostate. 2018 06; 78(8):616-622.
Score: 0.125
-
Goldstein J, Goyal R, Roland JT, Gellert LL, Clark PE, Hameed O, Giannico GA. MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: ?A Comparison With AMACR. Am J Clin Pathol. 2016 Sep; 146(3):294-302.
Score: 0.113
-
Goldstein J, Borowsky AD, Goyal R, Roland JT, Arnold SA, Gellert LL, Clark PE, Hameed O, Giannico GA. MAGI-2 in prostate cancer: an immunohistochemical study. Hum Pathol. 2016 06; 52:83-91.
Score: 0.108
-
Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA, Clark PE, Bhowmick NA. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008 Dec 01; 14(23):7790-7.
Score: 0.066
-
Yacoub J, Richardson C, Farmer M, Lee WR, Clark PE, Hurt G, Levine EA. Male breast cancer during treatment with leuprolide for prostate cancer. Clin Adv Hematol Oncol. 2007 Jul; 5(7):555-6; discussion 556-7.
Score: 0.060